WashU Expert: Five holiday talking points for families facing aging, end-of-life decisions

WashU Expert: Five holiday talking points for families facing aging, end-of-life decisions

Few things are as certain as the end of life, so why is it so hard to talk about? That’s a question that many families will be grappling with over the holidays. And while it’s easy to put off dark discussions during festive times, it’s best to have them sooner than later, says Brian Carpenter, a psychologist who studies family relations in later life at Washington University in St. Louis.
WashU Expert: Better health care not enough to address health disparities

WashU Expert: Better health care not enough to address health disparities

More and better health care will be necessary, but not sufficient, to advance better overall population health and to address lingering health disparities, says Jason Purnell, an expert on public health at Washington University in St. Louis. Purnell has written a chapter in the newly released book “What It’s Worth: Strengthening the Financial Future of Families, Communities, and the Nation.”

WashU Expert: Navigating Cyber Week

​​Millions of consumers are expected to make online purchases during Cyber Week. How can they find the best deals? Selin A. Malkoc, PhD, associate professor of marketing at Olin Business School at Washington University in St. Louis, provides some advice and answers.​
WashU Expert: Who were the Pilgrims?

WashU Expert: Who were the Pilgrims?

Who were the Pilgrims? Who were the Puritans? And how did they view Native Americans? As the annual Thanksgiving holiday approaches, Abram Van Engen, PhD, assistant professor of English in Arts & Sciences at Washington University in St. Louis, discusses the beliefs of the two groups, the differences between them and the theology of sympathy.
WashU Expert: Pfizer deal marks the end of U.S. ability to stop corporate tax inversion

WashU Expert: Pfizer deal marks the end of U.S. ability to stop corporate tax inversion

U.S. pharmaceutical giant Pfizer announced Nov. 23 a record-breaking $160 billion merger with Irish firm Allergan, the biggest merger to date involving the controversial strategy of tax inversion. The move marks the beginning of the end of the ability to stop corporate tax inversions under current tax rules, said Adam Rosenzweig, JD, professor of law and an expert on international tax law at Washington University in St. Louis.
View More Stories